Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025International Journal of Molecular SciencesOpen Access

Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ANA. NgaiABAqsa BaigMZMuhammad Anjum Zia

Discussion

Loading...

Member takes

Overview

Retrospective cohort study finds ARB monotherapy slightly improves renal function over SGLT2i/ACEi, suggesting treatment considerations.

Key Points

  • ARB monotherapy was associated with better renal function markers than SGLT2i/ACEi therapy, with higher eGFR and lower serum creatinine levels.
  • In this longitudinal study, 60.8% of ARB users maintained negative albuminuria compared to 73.1% on combination therapy, indicating renal stability.
  • With a sample of 126 patients, renal biomarkers were rigorously analyzed using t-tests and ANOVA to derive comparative effectiveness.
  • These results emphasize the need for further studies to understand the long-term renal effects of varying diabetes treatment regimens.

Cite This Study

Ngai et al. (2025) studied this question.

synapsesocial.com/papers/68c241acb210217d6479fd8ahttps://doi.org/10.3390/ijms26157412
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data2026
  2. 2Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.2025 · 4 citations
  3. 3ACE Inhibitors vs ARBs in Hypertensive Diabetics: A systematic review of cardiovascular mortality and renal outcomes2025
  4. 41393-P: Comparative Efficacy of Use of Combined Finerenone and Conventional Dose Angiotensin II Receptor Blockers vs. High-Dose ARB on Renal Markers in T2DM Patients with Stage 1–3 Diabetic Nephropathy Receiving SGLT2i2026
  5. 5Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs2025